Moderna Announces Data to be Presented at ESMO Congress 2025

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, which will be held October 17-21, 2025 in Berlin, Germany. This includes a mini oral presentation on mRNA-4359, Moderna's investigational mRNA-based therapy designed to elicit T-cell immune responses against tumor and immunosuppressive cells, as well as two poster presentations on intismeran autogene (V940/mRNA-4157). Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.

Text size:

The details of the presentations are as follows:

Presentation #1515MO: Clinical Outcomes and PD-L1 Expression Analyses from a Trial of mRNA-4359 Plus Pembrolizumab in Checkpoint Inhibitor-Resistant/Refractory (CPI-R/R) Melanoma
Mini Oral Presentation: October 17, 2025, 2:00 - 3:30 PM CET
Location: Nuremberg Auditorium - Hall 5.2
Presenter: David J. Pinato
Presentation #3135eTiP: INTerpath-011: Phase 2 study of intismeran autogene (V940/mRNA-4157) plus bacillus Calmette-Guérin (BCG) versus BCG alone for high-risk (HR) non-muscle-invasive bladder cancer (NMIBC)
Presenter: Petros Grivas
Presentation #1684TiP: Intismeran autogene (V940/mRNA-4157) + pembrolizumab versus pembrolizumab alone as first-line therapy for advanced melanoma: the phase 2 INTerpath-012 study
Presenter: Paolo A. Ascierto

Moderna Investor Event

Moderna will host an analyst event while at ESMO. Details of the event to follow.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Moderna Contacts

Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
[email protected]

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

P.Martin--AMWN

RBGPF	0%	80.22	$
CMSC	0%	23.12	$
BCC	-0.7%	73.715	$
JRI	0.06%	13.378	$
AZN	1.12%	92.59	$
NGG	0.87%	77.08	$
SCS	0.12%	16.14	$
RIO	1.09%	80.98	$
GSK	0.74%	48.95	$
CMSD	0.09%	23.22	$
RYCEF	0.64%	15.6	$
RELX	-0%	40.98	$
BTI	0.39%	56.99	$
BCE	0.09%	22.75	$
BP	1.33%	34.6	$
VOD	1.15%	13.03	$

American Marconi Wireless News - Moderna Announces Data to be Presented at ESMO Congress 2025

Moderna Announces Data to be Presented at ESMO Congress 2025

Featured

New Epstein files dump contains multiple Trump references

Killer in Croatia school attack gets maximum 50-year sentence

Amazon says blocked 1,800 North Koreans from applying for jobs

Australian state poised to approve sweeping new gun laws, protest ban